Rheumnow Podcast

Quiz Talk (5.22.2026)

Dr. Jack Cush talks of birthdays, Quizes and journal articles this week on the podcast.

Infectious Rheumatology (5.15.2026)

Dr. Jack Cush discusses his favorite journal articles from the past week on RheumNow.com.

Influential Rheumatoid Factors(5/8/2026)

Dr Jack Cush reviews the news and journal reports from last weekon rheumnow.com

Great Lectures; Great Presentations

Dr. Jack Cush lectures on giving a great presentation; based on 40 years of lecturing in Rheumatology.

DERM on RheumNow (April 2026)

The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects. 

Features Dr. Jack Cush, Editor at RheumNow.com.

Show Notes:

Chinese target emulation trial of MDA-5+, dermatomyositis w/ ILD. 106 Rx w/ UPA & 328 w/ TOFA. 6-month lung transplantation-free survival 72% vs 67% (UPA v TOFA). UPA non-inferior to TOFA in MDA5+DM-ILD https://t.co/BBAfbM06AM

In 2025 DTC TV ad spending by top 10 incr to $2.67 billion (up from $2.1 B). Rheum Drugs in top 3: 1. Skyrizi $440 million 2. Tremfya $431 M 3. Rinvoq $376 M https://t.co/EsWgUqUy9Z

2. Dermatology Salaries 2025 – Dermatology is top 10 at $448K according to Medscape; expected to go down -1% in 2026; derms made up 2% of survey group 37K MDs

3. Itch is common in Scleroderma (SSc) and not related to Dz duration. Study of 2173 Pts (~20K itch assessments), 87 F; mean age 55 yrs; 40% w/ diffuse SSc. Itch (moderate 4/10) seen in ~35% at all times https://t.co/QnT8d0xA5Z

4. Asia-Pacific Lupus study of Mucocutaneous activity (MC-A) in 4102 SLE pts. 36% had MC-A (rash 1055; alopecia 731; m ulcers 352); 15% persistently. MC-A assoc w/ W, smoking, +serologies, vasculitis, myositis, serositis, nephritis, NP-SLE https://buff.ly/D5fXJdY

5. Predictors of Calcinosis Cutis in Systemic Sclerosis  

6. AFFINITY Study - Combination Biologic Therapy in PsA A pilot trial assessed the efficacy and safety of the guselkumab+golimumab (COMBO) combination versus GUS monotherapy in active PsA (failing a prior tumor necrosis factor inhibitor (TNFi-IR) and showed superiority in ACR 50 https://t.co/f2CB8FnZMB

7. AAD 2026 Annual Mtg presents new data on another TYK2 inhibitor. In 2 phase 3 RCTs (ONWARD1 ONWARD2) envudeucitinib was superior to placebo & apremilast in 1700 plaque psoriasis pts https://t.co/DPlzDw5m7N

8. Among 1074 #PsA tested annually, RF positivity was found in 16.1% overall (5.1% RF+ at baseline). RF+ rediced odds of MDA (OR 0.53) w/ incr risk of bDMARD discontinuation (OR 2.65) https://buff.ly/BsM7NKQ

9. The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis - Review

10. Ixekizumab With Tirzepatide Efficacy in Obese Psoriatic Arthritis

11. Brepocitinib in Dermatomyositis

Follow the Money (4.23.2026)

Dr. Jack Cush follows the money and all the news that fits the Rheumatology Gab for this past week.

Prescribing Lessons (4.17.2026)

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.

Top Four and More (4.10.2026)

Dr. Jack Cush reviews the news and journal reports from RheumNow.com this week - including his top four favorite subjects.

Whats New PsA? (4.3.2026)

Dr. Jack Cush reviews the news and major articles from this week, including FDA safety warnings, reports from AAD, PsA trials.

PsA GRAPPA Domains: Outcomes With a JAKi

Dr. Schwartzman and Dr. Ruderman discuss how PsA disease activity across GRAPPA domains may guide treatment decisions, sharing both the evidence for and their experience with a JAKi across domains.
Sponsored by AbbVie Medical Affairs + Health Impact